Melinda L. Telli, M.D.
Academic Appointments
- Instructor, Medicine - Oncology
Contact Information
-
Clinical Offices
Oncology 875 Blake Wilbur Dr Clinic F Stanford, CA 94305-5826 Tel Work (650) 498-6000 Fax (650) 725-9113
- Academic Offices
Administrative Contact Oncology Clinic Tel Work 650-498-6000Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Cancer > Breast Cancer
- Breast Cancer - Medical Oncology
- Triple-negative breast cancer
- Locally advanced breast cancer
- Oncology
Honors and Awards
- Young Investigator Award, American Society of Clinical Oncology (2009)
- Fellowship Award, Susan G. Komen for the Cure (2008)
- Merit Award, American Society of Clinical Oncology (2008)
- Alpha Omega Alpha, George Washington University (2002)
- Alec Horowitz First Year Scholar Award, George Washington University (1999)
Professional Education
| B.A.: | University of Pennsylvania, Biology, with Distinction (1996) |
| M.D.: | George Washington University, Medicine, with Distinction (2002) |
| Residency: | Stanford University, Internal Medicine (2005) |
| Fellowship: | Stanford University, Medical Oncology (2008) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (2005) |
Community & International Work
Scientific Focus
Research Interests
My research focuses on breast cancer treatment and survivorship. Active areas of investigation include novel treatments for triple-negative breast cancer, prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
Clinical Trials
- B-Receptor Signaling in Cardiomyopathy Recruiting
- Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer Recruiting
- Phase II Gemcitabine, Carboplatin & PARP Inhibitor BSI-201 in Neoadjuvant Tx of Triple-Neg Breast CA Recruiting
- Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Recruiting
Publications
- First-line chemotherapy for metastatic breast cancer. Clin Breast Cancer. 2009: S66-72
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008; (9): 1613-8
- Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007; (23): 3525-33
- Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007; (3): 324-30
- Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells. Biochem Pharmacol. 1999; (4): 425-32
Help